ENQUIRY

Fraud Warning Disclaimer : FDI India warns you against certain individuals that might falsely present themselves as our affiliate agents, representatives, or employees. Under this false pretence, they might try to gain access to your personal information or to acquire money as Consultation fee or any other form or other valuables from you by offering fictitious employment opportunities or by claiming that they are contacting you on our behalf. Don’t fall prey into the fraudulent misrepresentation. Such fraudulent claims and offers are received generally via email, text message, phone, or internet, etc.

FDI India would like to bring to your notice that our authorized official Email IDs are [email protected], [email protected], [email protected], and Contact Numbers 0120-7195400, 9560023760, and 8882033433. FDI India shall not be liable for any claims, damage, or loss of any kind inflicted by any other unauthorized entity. Be very mindful of such scams.

Legal : We own all the information, images, text, logo, and other content provided by us. The use of information is strictly prohibited without our consent. We hold the right to take a legal action against any individual or organization violating or using our site information.

BIOTECHNOLOGY

FDI In Biotechnology Sectors

Name: FDI India
Address: 207, 2nd Floor, Tower 1, Assotech Business Cresterra, Plot No- 22 Sector 135, Noida, 201301, IN
Telephone: 9560023760
Price range: INR
Rating: 4.9

The biotechnology sector in the country has played a significant role in enhancing India’s global profile. India stands among the top 12 biotech destinations in the world and ranks third in the Asia Pacific, with approximately 3% share in the global biotechnology industry. The Biotechnology industry in India, comprising about 800 companies, assumes a critical role in the Indian economy. Biopharma is the largest sector contributing about 62 per cent of the total revenue followed by bio-services (18 per cent), bio-agri (15 per cent), bio-industry (4 per cent), and bio-informatics contributing (1 per cent).

By 2020, bio-incubation space of 175,000 sq. ft. has been planned with the target to support 50 world class bio-incubators. By 2025, Indian Biotechnology industry is expected to reach $100 bn.

100% FDI for biotechnology sector is allowed under the automatic route for green-field pharma.

100% FDI in biotechnology is allowed under the government route for brownfield pharma in up to 74% FDI is under automatic route and beyond 74% is under the government approval route.

Up to 100% FDI in biotechnology in India is allowed under the automatic route for the manufacturing of medical devices.

150 %

Tax deduction on R&D expenditure
57.1 %

Annual industrial growth
64 %

Bio-pharma revenue share
18 %

Share in Bio-services

1

World’s largest producer of recombinant Hepatitis B vaccine
2

World’s largest 2-wheeler and 3-wheeler manufacturer
3

World’s 3rd largest heavy truck manufacturer and 4th largest car manufacturer

The sector is divided into five major segments- Bio-pharma, Bio-services, Bio-agri, Bio-industrial, and Bio-informatics
The biopharmaceutical sector accounts for the largest share of the biotech industry with a share of 64% of total revenues, followed by bio-services with 18% market share
India is becoming a leading destination for clinical trials, contract research, and manufacturing activities, which is further fuelling the growth of the bio-services sector
Bio-agri segments accounted for 14% of the biotech industry in 2015-16, while the remaining market is catered by bio-industrial (3%) and bio-informatics (1%)
India's Serum Institute is the largest Bio-pharma company in the country and accounts for approximately 22% of the biopharma market
30 bio-incubators and biotech parks have been supported and established during April 2014-September 2016

Growing population
India to become the world’s most populous country by 2030
Rising demand for treatments
Increased insurance penetration and a growing burden of disease
Medical infrastructure facilities
$ 200 Bn expenditure planned on medical infrastructure over the next decade
Strong skilled manpower pool
‘National Biopharma Mission’, an Industry-Academia mission to skill the workforce
Cost competitive manufacturing
Development of life-science clusters builds collaborations between research institutes and the private sector

Jul 2016: Helix investment Holdings Pte Ltd., Singapore invested $12 mn in Concord Biotech Ltd
Aug 2015: Tano India Pvt., Mauritius invested $7.4 mn in Windlas Biotech Ltd.